Evidence of chromosome regions and gene involvement in inflammatory breast cancer

International Journal of Cancer

Volumn 102, Issue 6, 2002, Pages 618-622

  Lerebours, Florence ^a,d   Bertheau, Philippe ^b   Bieche, Ivan ^a   Driouch, Keltouma ^a   De The, Hugues ^b   Hacene, Kamel ^a   Espie, Marc ^b   Marty, Michel ^c   Lidereau, Rosette ^a  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE RENÉ HUGUENIN   (France)

Author keywords

Inflammatory breast cancer; LOH; Tumor suppressor genes

Indexed keywords

DNA;

ALLELE; ARTICLE; BREAST CANCER; CHROMOSOME; GENE AMPLIFICATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0037146739     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10729     Document Type: Article

References (33)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol 1992;10:1014-24.
2. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922-7.
3. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and noninflammatory breast cancer: Prognostic significance. Int J Cancer 1989;43:201-8.
4. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 1993;85:1765-7.
5. Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M, Riou G. Association of c-erbB2-gene amplification with poor prognosis in noninflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 1994;58:763-8.
6. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: Clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-9.
7. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-6.
8. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 2000;60:3706-12.
9. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, Buecher B, Martinet N, Galateau F, Thomas G. Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer 1999;81:854-8.
10. Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Turpin E, Lidereau R, de The H, Janin A. Allelic loss detection in inflammatory breast cancer: Improvement with laser microdissection. Lab Invest 2001;81:1397-402.
11. Gower JC. Fisher's optimal scores and multiple correspondence analysis. Biometrics 1990;4:947-61.
12. Harman HH. Modern Factor Analysis. Chicago: The University of Chicago Press, 1967.
13. Cornelisse CJ, Kuipers-Dijkshoorn N, van Vliet M, Hermans J, Devilee P. Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 1992;50:544-8.
14. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
15. Iwase H, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, Nakamura T, Kobayashi S. The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers. Breast Cancer 1997;4:234-8.
16. Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997;57:5469-74.
17. Driouch K, Briffod M, Bieche I, Champeme MH, Lidereau R. Location of several putative genes possibly involved in human breast cancer progression. Cancer Res 1998;58:2081-6.
18. Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, Caligo MA, Lidereau R, Lindblom A, Seitz S, Kelsell D, Hamann U, et al. Consortium study on 1280 breast carcinomas: Allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 1998;58:1004-12.
19. Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, Rio P, Champeme MH, Bieche I, Birnbaum D, White G, Sztan M, Sever N, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer 1999;25:212-21.
20. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-82.
21. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59:1973-9.
22. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L. Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 2001;93:121-7.
23. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
24. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
25. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999;59:3866-9.
26. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-5.
27. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998;16:3151-7.
28. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001:61:3105-9.
29. Hamann U, Herbold C, Costa S, Solomayer EF, Kaufmann M, Bastert G, Ulmer HU, Frenzel H, Komitowski D. Allelic imbalance on chromosome 13q: Evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res 1996;56:1988-90.
30. Bieche I, Lidereau R. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinogen 2000;29:151-8.
31. Bieche I, Nogues C, Lidereau R. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 1999;18:5232-8.
32. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 1999;18:1957-65.
33. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.